Carole Ho Sells 12,255 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now directly owns 178,580 shares of the company’s stock, valued at approximately $3,610,887.60. This trade represents a 6.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Denali Therapeutics Trading Up 0.3 %

Shares of DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. The firm’s 50 day moving average is $24.23 and its 200-day moving average is $24.86. The stock has a market capitalization of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company posted ($0.72) earnings per share. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after buying an additional 22,900 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Denali Therapeutics by 4.5% in the 2nd quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock valued at $4,160,000 after purchasing an additional 7,766 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Denali Therapeutics by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock valued at $769,000 after purchasing an additional 2,730 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Denali Therapeutics by 13.7% in the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after purchasing an additional 63,058 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock worth $32,913,000 after buying an additional 84,522 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DNLI shares. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. HC Wainwright decreased their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a report on Monday, December 16th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $31.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.